Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for California Nanotechnologies's Debt-to-EBITDA or its related term are showing as below:
FRA:R14'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.45 Med: 4.2 Max: 28.01
Current: -0.99
During the past 13 years, the highest Debt-to-EBITDA Ratio of California Nanotechnologies was 28.01. The lowest was -5.45. And the median was 4.20.
FRA:R14's Debt-to-EBITDA is ranked worse than 100% of 1246
companies
in the Chemicals industry
Industry Median: 2.11
vs FRA:R14: -0.99
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
California Nanotechnologies Debt-to-EBITDA Related Terms
California Nanotechnologies Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:R14 vs LIN, SHW, ECL: Debt-to-EBITDA Comparison
For the Specialty Chemicals subindustry, California Nanotechnologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
California Nanotechnologies Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, California Nanotechnologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where California Nanotechnologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (May. 2026) EBITDA data.
California Nanotechnologies (FRA:R14) has a Debt-to-EBITDA of -1.05 as of May. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on California Nanotechnologies. According to the industry distribution chart, California Nanotechnologies ranks #999999 out of 1246 companies in the Chemicals industry.
Is California Nanotechnologies' Debt-to-EBITDA too high?
California Nanotechnologies' current Debt-to-EBITDA is -1.05. Based on the distribution chart, California Nanotechnologies ranks #999999 out of 1246 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, California Nanotechnologies has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does California Nanotechnologies' Debt-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, California Nanotechnologies ranks #999999 out of 1246 companies for Debt-to-EBITDA. This places California Nanotechnologies in the lower half of its industry. The industry median Debt-to-EBITDA is 2.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.11, based on 1,246 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on California Nanotechnologies. For the Chemicals industry, the median Debt-to-EBITDA is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. California Nanotechnologies's current Debt-to-EBITDA is -1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is California Nanotechnologies stock overvalued right now?
Based on GuruFocus' analysis, California Nanotechnologies (FRA:R14) is currently considered Fairly Valued. The stock's GF Value™ is €0.18, compared to a current price of €0.17 — trading 6.4% below its estimated fair value. The current Debt-to-EBITDA is -1.05. California Nanotechnologies' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For California Nanotechnologies (FRA:R14), the current Debt-to-EBITDA is -1.05 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is California Nanotechnologies (FRA:R14) Overvalued in 2026?
Based on GuruFocus' analysis, California Nanotechnologies stock appears to be undervalued.
The current stock price of €0.17 is trading 6.4% below its estimated GF Value™ of €0.18.
GuruFocus considers California Nanotechnologies to be Fairly Valued.
Key valuation signals for FRA:R14:
Debt-to-EBITDA: -1.05
GF Value™: €0.18 vs. price of €0.17 (6.4% below fair value)
No single metric tells the full story. See the FRA:R14 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
California Nanotechnologies Corp engages in the production, and research and development of nanostructured components and materials. Its products include High-Strength Graphite Spark tooling, Plasma Sintering Tooling, Tungsten Carbide Tooling, Carbon Graphite Foil, Carbon Felt and Yarn, and others.
36GF Score
Get the complete analysis for FRA:R14
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R14 has been successfully added to your 
